Literature DB >> 11304107

The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

D G Altman1, K F Schulz, D Moher, M Egger, F Davidoff, D Elbourne, P C Gøtzsche, T Lang.   

Abstract

Overwhelming evidence now indicates that the quality of reporting of randomized, controlled trials (RCTs) is less than optimal. Recent methodologic analyses indicate that inadequate reporting and design are associated with biased estimates of treatment effects. Such systematic error is seriously damaging to RCTs, which boast the elimination of systematic error as their primary hallmark. Systematic error in RCTs reflects poor science, and poor science threatens proper ethical standards. A group of scientists and editors developed the CONSORT (Con solidated S tandards o f R eporting T rials) statement to improve the quality of reporting of RCTs. The statement consists of a checklist and flow diagram that authors can use for reporting an RCT. Many leading medical journals and major international editorial groups have adopted the CONSORT statement. The CONSORT statement facilitates critical appraisal and interpretation of RCTs by providing guidance to authors about how to improve the reporting of their trials. This explanatory and elaboration document is intended to enhance the use, understanding, and dissemination of the CONSORT statement. The meaning and rationale for each checklist item are presented. For most items, at least one published example of good reporting and, where possible, references to relevant empirical studies are provided. Several examples of flow diagrams are included. The CONSORT statement, this explanatory and elaboration document, and the associated Web site ( http://www.consort-statement.org ) should be helpful resources to improve reporting of randomized trials. Throughout the text, terms marked with an asterisk are defined at end of text.

Mesh:

Year:  2001        PMID: 11304107     DOI: 10.7326/0003-4819-134-8-200104170-00012

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  879 in total

Review 1.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Are randomised controlled trials in the BMJ different?

Authors:  M Egger; C Bartlett; P Jüni
Journal:  BMJ       Date:  2001-11-24

4.  Better standards for better reporting of RCTs.

Authors:  P M Bossuyt
Journal:  BMJ       Date:  2001-06-02

Review 5.  The revised CONSORT statement: honing the cutting edge of the randomized controlled trial.

Authors:  S Shapiro
Journal:  CMAJ       Date:  2001-04-17       Impact factor: 8.262

6.  Reporting the clinical importance of randomized controlled trials.

Authors:  David Moher; Douglas G Altman; Kenneth F Schulz
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

7.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  David Moher; Kenneth F Schulz; Douglas G Altman
Journal:  Clin Oral Investig       Date:  2003-01-31       Impact factor: 3.573

8.  Homeopathic arnica.

Authors:  Peter Fisher; Robert Mathie; Robbert van Haselen
Journal:  J R Soc Med       Date:  2003-04       Impact factor: 5.344

9.  CONSORT statement requires closer examination.

Authors:  Douglas G Altman; Kenneth F Schulz; David Moher
Journal:  BMJ       Date:  2002-12-07

Review 10.  Are physicians willing to ration health care? Conflicting findings in a systematic review of survey research.

Authors:  Daniel Strech; Govind Persad; Georg Marckmann; Marion Danis
Journal:  Health Policy       Date:  2008-12-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.